Home › Squamous Cell Carcinoma ng Ulo at Leeg › Kentucky › Louisville
Pag-aaral pangklinika para sa Squamous Cell Carcinoma ng Ulo at Leeg sa Louisville, KY
Isang pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Louisville. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Nagre-recruitPhase 2/3
- Site#0111, Louisville
- Site#0115, Louisville
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 2
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Nagre-recruitPhase 1
- Norton Cancer Institute, Louisville
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Nagre-recruitPhase 2
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 2
- Norton Cancer Institute, Louisville
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Nagre-recruitPhase 2
- Baptist Health Floyd, New Albany · 4 mi ang layo
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
Nagre-recruitPhase 3
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Nagre-recruitPhase 1/2
- Norton Cancer Institute, Louisville
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Nagre-recruitPhase 1/2
- Norton Cancer Institue Downtown, Louisville
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Nagre-recruitPhase 1
- Norton Cancer Institute /ID# 248903, Louisville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Research Site 115, Louisville
Pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg sa ibang lungsod
- Houston, TX47 pag-aaral
- Los Angeles, CA42 pag-aaral
- Boston, MA40 pag-aaral
- New York City, NY39 pag-aaral
- Nashville, TN39 pag-aaral
- St. Louis, MO28 pag-aaral
- Arlington, VA26 pag-aaral
- Philadelphia, PA26 pag-aaral
- Chicago, IL26 pag-aaral
- Atlanta, GA24 pag-aaral
- San Antonio, TX22 pag-aaral
- New Haven, CT22 pag-aaral
Iba pang pag-aaral sa Louisville
- Non-Small Cell Lung Cancer22 pag-aaral
- Obesity17 pag-aaral
- Overweight15 pag-aaral
- Kanser (lahat ng uri)14 pag-aaral
- Pagkabigo ng Puso13 pag-aaral
- Acute Myeloid Leukemia12 pag-aaral
- Multiple Myeloma12 pag-aaral
- Kanser sa Ovary12 pag-aaral
- Kanser sa Suso11 pag-aaral
- Kanser sa Baga11 pag-aaral
- Melanoma10 pag-aaral
- Kanser sa Prostate10 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.